Clinicopathological and Prognostic Significance of CBX3 Expression in Human Cancer: a Systematic Review and Meta-analysis

Figure 4

Forest plots for the association between CBX3 expression and in cancer patients: (a) age (≥65 vs. <65 years); (b) age (≥60 vs. <60 years); (c) age (≥50 vs. <50years); (d) gender (male vs. female); (e) tumor size (>5 vs. ≤5 cm); (f) tumor size (>3 vs. ≤3 cm); (g) lymph node metastasis (N+ vs. N0); (h) distant metastasis (M+ vs. M0); (i) degree of differentiation (well+moderate vs. poor). Abbreviations: SE: standard error; CI: confidence interval; IV: inverse variance; OR: odds ratio.

(a) Age (≥65 vs. <65years)

(b) Age (≥60 vs. <60years)

(c) Age (≥50 vs. <50years)

(d) Gender (male vs. female)

(e) Tumor size (>5 vs. ≤5 cm)

(f) Tumor size (>3 vs. ≤3 cm)

(g) Lymph node metastasis (N+ vs. N0)

(h) Distant metastasis (M+ vs. M0)

(i) Degree of differentiation (well+moderate vs. poor)